Praxis Precision Medicines
PRAX
250 hedge funds and large institutions have $8.69B invested in Praxis Precision Medicines in 2025 Q4 according to their latest regulatory filings, with 115 funds opening new positions, 87 increasing their positions, 44 reducing their positions, and 15 closing their positions.
700% more funds holding in top 10
Funds holding in top 10: 3 → 24 (+21)
667% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 15
564% more capital invested
Capital invested by funds: $1.31B → $8.69B (+$7.38B)
98% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 44
64% more funds holding
Funds holding: 152 → 250 (+98)
0.66% more ownership
Funds ownership: 117.18% → 117.84% (+0.66%)
8% less call options, than puts
Call options by funds: $219M | Put options by funds: $238M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$245M |
| 2 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$234M |
| 3 |
Janus Henderson Group
London,
|
+$88.7M |
| 4 |
Barclays
London,
United Kingdom
|
+$84.6M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$81.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$262M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$187M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$92.4M |
| 4 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$72.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$58.1M |
PRAX Hedge Fund Activity: Q4 2025 in Review
250 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2025, worth a combined $8.69B — up 564% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new PRAX positions and 15 closed out — a net gain of 100 holders — while 87 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $245M. The largest seller was Adage Capital Partners, cutting an estimated $262M.
- 250 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2025, up from 152 in Q3 2025.
- Funds reported $8.69B of Praxis Precision Medicines stock for Q4 2025, up 564% quarter-over-quarter.
- 115 funds opened new Praxis Precision Medicines positions in Q4 2025 and 15 closed out, a net change of +100 holders.
- The largest Praxis Precision Medicines buyer in Q4 2025 was Fidelity Investments, an estimated $245M added.
- The largest Praxis Precision Medicines seller in Q4 2025 was Adage Capital Partners, an estimated $262M sold.
Based on aggregated 13F filings for Q4 2025.